Atrium Therapeutics emerged from Avidity Biosciences with a $270 million launch financing to pursue two RNA therapy programs targeting rare inherited cardiomyopathies. The spin‑out follows Novartis’s acquisition of Avidity and positions Atrium to advance its pipeline toward the clinic with substantial capital. Management emphasized the programs’ rapid path to first‑in‑human studies and the dearth of approved therapies for the targeted conditions. Investors including strategic biotech backers joined the round, signaling appetite for RNA modalities focused on cardiology. Atrium’s fundraising underscores continued investor interest in RNA platforms beyond liver and central nervous system targets, and the company’s execution on clinical milestones will be watched as an indicator for cardiology‑focused nucleic acid therapeutics.